Comparative Evaluation of Lipid Profile and Inflammation for prediction of Cardiac Medical Complications and Handling
The Prognostic Value of Lipid Profiles and Inflammation in Cardiovascular Disease
DOI:
https://doi.org/10.69750/dmls.01.06.057Keywords:
Lipid profile, cardiovascular diseases, dyslipidaemia, cardiac complications, statins, prediction, therapeutic interventions.Abstract
Background:Cardiovascular complications are predominant cause of global morbidity and mortality, dyslipidemia and inflammation representing critical risk factors contributing to their prevalence.
Objective: The purpose of this research was to determine the Lipid Profile levels and inflammatory biomarkers as risk predictors for the cardiac complications and also to compare the clinical results of patients with normal and abnormal lipid profile.
Methodology: The present study was A case-control study conducted over 12 months involving 400 patients who were selected and divided into two groups. Group- A with normal lipid profile and Group B with dyslipidaemia. The biomarkers for Serum lipid profiles were included blood serum levels of LDL, HDL, triglycerides, Cholesterol and for inflammations, CRP and IL-6 were tested. Data analysis was done using SPSS version 27.0 using paired and independent t-tests, MANOVA, and Pearson correlation statistical tests.p≤0.05 was considered statistically significant.
Results: Group B showed a high percentage of cardiac complications 28 % as compared to group A with only 10% of complications (p<0.01). It was found that LDL-C, HDL-C, and CRP are the good predictors of cardiac events. There was a decrease in LDL-C in Group B (p < 0.001) after statin treatment; however, the inflammatory markers were still high in Group B, which implies that they still posed cardiovascular risk. The Pearson correlation analysis revealed positive correlation between increased CRP and cardiac complications and increased LDL-C and cardiac complications; r= 0. 62; r = 0. 57 respectively.
Conclusion: High LDL-C, low HDL-C and high CRP values serve as accurate indicators of cardiac diseases. Although, implementation of lipid-lowering therapy successfully lowered the LDL-C level, persistent inflammation was a factor that maintained cardiovascular risk.
Downloads
References
Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:971453. doi:10.1155/2015/971453
Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061-8. doi:10.1001/jama.2013.280532
Naeem M, Khattak RM, Rehman MU, Khattak MNK. The role of glycated hemoglobin and serum lipid profile measurements to detect cardiovascular diseases in type 2 diabetic patients. South East Asia J Public Health. 2016;5(2):30-4. doi:10.3329/seajph.v5i2.28310
Loor MVP, Quijije MAO, Fleitas DG, Dolores CM. Comparative analysis of the lipid profile before and after application of the nursing strategy. Int J Health Sci. 2022;6(1):509-18. doi:10.53730/ijhs.v6n1.6280
Swathy M, Saruladha K. A comparative study of classification and prediction of cardiovascular diseases using machine learning and deep learning techniques. ICT Express. 2022;8(1):109-16. doi:10.1016/j.icte.2021.08.021
Lee S, Zhou J, Wong WT, Liu T, Wu WKK, Wong ICK, et al. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. BMC Endocr Disord. 2021;21(1):94. doi:10.1186/s12902-021-00751-4
Shabana, Shahid SU, Sarwar S. The abnormal lipid profile in obesity and coronary heart disease in Pakistani subjects. Lipids Health Dis. 2020;19(1):73. doi:10.1186/s12944-020-01248-0
Mohd Faizal AS, Thevarajah TM, Khor SM, Chang S-W. A review of risk prediction models in cardiovascular disease: conventional approach vs artificial intelligence. Comput Methods Programs Biomed. 2021;207:106190. doi:10.1016/j.cmpb.2021.106190
Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high-density lipoprotein cholesterol in people with diabetes and cardiovascular risk: systematic review and network meta-analysis. BMJ. 2022;376:e067731. doi:10.1136/bmj-2021-067731
Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride–glucose index in prediction of adverse cardiovascular events in premature CAD patients: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142. doi:10.1186/s12933-022-01576-8
Kaneko H, Itoh H, Kiriyama H, Kamon T, Fujiu K, Morita K, et al. Lipid profile and subsequent cardiovascular disease among young adults aged <50 years. Am J Cardiol. 2021;142:59-65. doi:10.1016/j.amjcard.2020.11.038
Wilson PWF, Jacobson TA, Martin SS, Jackson EJ, Le NA, Davidson MH, et al. Lipid measurements in cardiovascular disease management: practical recommendations. J Clin Lipidol. 2021;15(5):629-48. doi:10.1016/j.jacl.2021.09.046
Sun JT, Chen Z, Nie P, Ge H, Shen L, Yang F, et al. Lipid profile features and associations with disease severity and mortality in COVID-19. Front Cardiovasc Med. 2020;7:584987. doi:10.3389/fcvm.2020.584987
Moussavi Javardi MS, Madani Z, Movahedi A, Karandish M, Abbasi B. Dietary fat quality indices and lipid profile correlation with atherogenic index among obese/non-obese adults. Lipids Health Dis. 2020;19(1):213. doi:10.1186/s12944-020-01387-4
Huang JB, Chen YS, Ji HY, Xie WM, Jiang J, Ran LS, et al. Neutrophil-to-HDL ratio as a prognostic marker in elderly MI patients. Lipids Health Dis. 2020;19(1):59. doi:10.1186/s12944-020-01238-2
Aggarwal DJ, Kathariya MG, Verma DPK. LDL-C, non-HDL-C and ApoB for cardiovascular risk assessment: searching for ideal markers. Indian Heart J. 2021;73(5):544-8. doi:10.1016/j.ihj.2021.07.013
Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. IL-6, CRP, and LDL-C as biomarkers of residual cardiovascular risk: analyses from CIRT. Eur Heart J. 2020;41(31):2952-61. doi:10.1093/eurheartj/ehaa160
Targher G, Corey KE, Byrne CD. NAFLD and cardiovascular disease: risk factors, prediction, and therapy. Diabetes Metab. 2021;47(2):101215. doi:10.1016/j.diabet.2020.101215
Parhofer KG, Laufs U. Lipid profile and lipoprotein(a) testing. Dtsch Arztebl Int. 2023;120(35–36):582-8. doi:10.3238/arztebl.m2023.0150
Abdalrada AS, Abawajy J, Al-Quraishi T, Islam SMS. Machine learning models for predicting co-occurrence of diabetes and cardiovascular diseases. J Diabetes Metab Disord. 2022;21(1):251-61. doi:10.1007/s40200-021-00968-z
Alloubani A, Nimer R, Samara R. Hyperlipidemia, cardiovascular disease, and stroke: a systematic review. Curr Cardiol Rev. 2021;17(6):e051121189015. doi:10.2174/1573403X16999201210200342
Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in cardiovascular risk. Int J Mol Sci. 2023;24(1):75. doi:10.3390/ijms24010075
Downloads
PlumX Metrics
Published
Issue
Section
License
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License , which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you must obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
How to Cite
